HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Update

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 12,800 shares, a growth of 212.2% from the August 31st total of 4,100 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 24,000 shares, the days-to-cover ratio is currently 0.5 days.

Hedge Funds Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Pullen Investment Management LLC purchased a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 85,116 shares of the company’s stock, valued at approximately $149,000. Pullen Investment Management LLC owned about 0.23% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is owned by hedge funds and other institutional investors.

HCW Biologics Stock Down 5.5 %

NASDAQ HCWB traded down $0.03 during trading hours on Friday, hitting $0.51. 981 shares of the company traded hands, compared to its average volume of 18,266. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.10 and a current ratio of 0.10. The business’s 50-day moving average is $0.55 and its 200-day moving average is $0.98. The stock has a market capitalization of $19.34 million, a price-to-earnings ratio of -0.67 and a beta of 0.78. HCW Biologics has a twelve month low of $0.40 and a twelve month high of $2.14.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter. The company had revenue of $0.62 million during the quarter. HCW Biologics had a negative net margin of 978.03% and a negative return on equity of 385.90%.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.